These 3 Gene-Editing CEOs Got Huge Raises Last Year
It’s no secret that the burgeoning field of gene-editing — a method of cutting out and replacing part of a gene — has generated serious buzz in the biotech world lately. New scientific tools like CRISPR/Cas9 have the potential to revolutionize the treatment of serious genetic disorders, and any company that can successfully commercialize the technology stands to reap a fortune.
But clouding the hype surrounding gene editing has been a complex and seemingly endless legal battle over who owns the rights to patents on CRISPR/Cas9, as well as the fact that the technology has yet to be tested in humans in the U.S.
But clouding the hype surrounding gene editing has been a complex and seemingly endless legal battle over who owns the rights to patents on CRISPR/Cas9, as well as the fact that the technology has yet to be tested in humans in the U.S.